Evopoint and SinoMab will receive USD $12 million in initial upfront payments and up to $549 million as future development, regulatory, and commerci...
XNW5004, an EZH2 inhibitor with independent intellectual property rights owned by Evopoint. As an epigenetic drug, it can regulate the expression of...
XNW 3009 is one of the new generation of selective hURAT1 inhibitors. Evopoint has enrolled the first patient in phase II clinical trial on April...
Follow us
